Document Detail


Effects of octreotide treatment on Graves' ophthalmopathy and circulating sICAM-1 levels.
MedLine Citation:
PMID:  8875747     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Efficacy of octreotide treatment for Graves' ophthalmopathy (GO) and the effects of this treatment on the serum levels of the circulating intercellular adhesion molecule-1 (sICAM-1) were evaluated. Ten patients with GO were treated with octreotide three daily SC injections of 100 micrograms, for 3 months. Octreotide treatment was initiated after restoration of euthyroidism with antithyroid drugs. All patients were treated with methimazole to maintain euthyroidism during the study. Sera were collected from all patients before and 3 months after initiation of the study, and from 20 age- and sex-matched healthy subjects for sICAM-1 measurement. sICAM-1 was measured by a sandwich ELISA method. Proptosis in all patients was evaluated by orbital CT scan before and 3 months after initiation of the study. Two of 10 patients did not respond to octreotide therapy, while the remaining eight patients showed regression or improvement after therapy. Octreotide therapy was particularly successful in patients with soft tissue involvement of GO (class II or III disease). Mean proptosis and ophthalmopathy index scores were significantly decreased after 3 months of octreotide therapy. Mean sICAM-1 levels were significantly higher in patients before octreotide therapy (470.5 +/- 52.6 ng/mL, p < 0.0001) when compared to normal subjects (186.5 +/- 53.3 ng/mL). Mean sICAM-1 levels were significantly decreased 3 months after octreotide therapy (from 478.7 +/- 52.6 to 415 +/- 42.8 ng/mL, p = 0.012) in the 8 patients who responded to therapy. In contrast, sICAM-1 levels remained unchanged or increased in two patients with poor response to octreotide therapy. Our results suggest that octreotide therapy could be a treatment modality in patients with GO. The mechanism by which octreotide acts on GO is not clear. The observed decrease in sICAM-1 levels during octreotide therapy suggests that octreotide may have immunomodulatory properties. Further investigation is needed to determine the optimal dose and duration of octreotide therapy.
Authors:
M Ozata; E Bolu; A Sengul; M Tasar; Z Beyhan; A Corakci; M A Gundogan
Related Documents :
19584187 - Growth hormone deficiency in patients with chronic heart failure and beneficial effects...
12118757 - Surgical treatment of pulmonary hydatid cysts: is capitonnage necessary?
10365547 - Prolactin response to the severity of surgical insult.
10407547 - Growth hormone therapy in patients with dilated cardiomyopathy: preliminary observation...
24360347 - Long-term degradation of poly-lactic co-glycolide/β-tricalcium phosphate biocomposite ...
3234417 - Infective endocarditis in children with congenital heart disease: the changing spectrum...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Thyroid : official journal of the American Thyroid Association     Volume:  6     ISSN:  1050-7256     ISO Abbreviation:  Thyroid     Publication Date:  1996 Aug 
Date Detail:
Created Date:  1997-01-23     Completed Date:  1997-01-23     Revised Date:  2005-11-17    
Medline Journal Info:
Nlm Unique ID:  9104317     Medline TA:  Thyroid     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  283-8     Citation Subset:  IM    
Affiliation:
Department of Endocrinology and Metabolism, Gulhane School of Medicine, Etlik-Ankara, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Autoantibodies / analysis
Female
Graves Disease / drug therapy*,  metabolism,  radiography
Hormones / adverse effects,  therapeutic use*
Humans
Injections, Subcutaneous
Intercellular Adhesion Molecule-1 / blood*
Male
Microsomes / immunology
Octreotide / adverse effects,  therapeutic use*
Thyroglobulin / immunology
Thyroxine / blood
Tomography, X-Ray Computed
Triiodothyronine / blood
Chemical
Reg. No./Substance:
0/Autoantibodies; 0/Hormones; 126547-89-5/Intercellular Adhesion Molecule-1; 6893-02-3/Triiodothyronine; 7488-70-2/Thyroxine; 83150-76-9/Octreotide; 9010-34-8/Thyroglobulin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Studies of retroorbital tissue xenografts from patients with Graves' ophthalmopathy in severe combin...
Next Document:  Sympathetic overactivity of intraocular muscles evaluated by accommodation in patients with hyperthy...